Heat Biologics rolls out $25M IPO; Akebia advances in anemia drug race;

@FierceBiotech: PR: Verastem receives orphan drug designation from the FDA for defactinib in mesothelioma. Release | Follow @FierceBiotech

@RyanMFierce: Roche highlights more upbeat PhIII data for 'breakthrough' leukemia contender. News | Follow @RyanMFierce

@EmilyMFierce: Scientists advocate for more responsible preclinical studies. Item | Follow @EmilyMFierce

> Chapel Hill-based Heat Biologics slipped through the IPO window with the sale of 2.5 million shares for $10 apiece, pricing at the low end of the company's proposed range of $10 to $12, while selling more than the expected 2.3 million shares. It trades under the symbol "HTBX." Article

> Akebia Therapeutics, an Ohio biotech group, has launched a Phase IIb study of AKB-6548, the company's lead candidate for anemia that mimics the body's response to high altitudes. GlaxoSmithKline ($GSK) and others are developing rival therapies. Release

Medical Device News

@FierceMedDev: Special Report: Top 10 Med Tech Investments of Q2. Feature | Follow @FierceMedDev

@MarkHFierce: U.K. researchers believe that low levels of a specific protein can signify aggressive colorectal cancer. More | Follow @MarkHFierce

@DamianFierce: Fresh deals and booming sales have Illumina brightening its 2013 guidance. News | Follow @DamianFierce

> Boston Scientific rolls out new imaging catheter in U.S., EU and Japan. Article

> Thermo lands another record quarter with Life on horizon. More

> Bard's costly lawsuits drown profits in Q2. Report

> FDA warns Prodigy Diabetes Care over glucose testing systems. Item

Pharma News

@FiercePharma: Lilly sales up 6%, to $5.93B; Cymbalta up 22% (!). Too bad it gets generic rivals later this year. Release | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Special report on the projected top 20 orphan drugs of 2018... see who made the list. Feature | Follow @CarlyHFierce

> FTC eyeing new patent deals for pay-for-delay action. Article

> GlaxoSmithKline sales tick up, but China probe will hit growth. Story

> GlaxoSmithKline CEO says HQ, British execs 'knew nothing' of China fraud. Report

Biomarkers News

> Epigenetic tags point to a new generation of age-related biomarkers. Report

> Nerves could predict aggressiveness of prostate cancer. More

> Takeda and Zinfandel advance Alzheimer's biomarker work. Story

> Plaque buildup trajectory may serve as a clue for Alzheimer's. Article

> Autism clues: UC Davis team spots two new potential biomarkers of the condition. Item

Drug Delivery News

 @MichaelGFierce: Regulus completes $49M public offering to support microRNA tech. Report | Follow @MichaelGFierce

> Novaliq secures CE mark for OTC drop to treat dry eye. News

> Supercomputer-designed hypertension drug mimics natural hormone response. Story

> Imprimis to begin osteoarthritis cream PhIII, snags transdermal wound treatment. More

> Cancer drug breaches blood-brain barrier using nanovesicles. Article

> Flowonix reports longest service life ever in 6-year Prometra trial. Item

And Finally... Derek Lowe writes about the story behind cancer immunotherapy work from the University of Pennsylvania, which has an ongoing collaboration on the technology with Novartis ($NVS). Blog post

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.